OrthoPediatrics Corp. (NASDAQ:KIDS) Receives Consensus Rating of “Moderate Buy” from Brokerages

Shares of OrthoPediatrics Corp. (NASDAQ:KIDS) have been given a consensus recommendation of “Moderate Buy” by the nine analysts that are presently covering the stock, Marketbeat reports. One analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and seven have issued a buy recommendation on the company. The average 1-year price objective among analysts that have issued ratings on the stock in the last year is $34.1429.

Several research analysts have commented on KIDS shares. Weiss Ratings reissued a “sell (e+)” rating on shares of OrthoPediatrics in a report on Saturday, September 27th. JMP Securities set a $35.00 price objective on shares of OrthoPediatrics and gave the company a “market outperform” rating in a report on Friday, August 8th. Citigroup reissued a “market outperform” rating on shares of OrthoPediatrics in a report on Friday, August 8th. BTIG Research dropped their price objective on shares of OrthoPediatrics from $40.00 to $39.00 and set a “buy” rating for the company in a report on Wednesday, August 6th. Finally, Wall Street Zen raised shares of OrthoPediatrics from a “sell” rating to a “hold” rating in a report on Saturday, August 9th.

Insider Activity at OrthoPediatrics

In other OrthoPediatrics news, CFO Fred Hite purchased 5,076 shares of the stock in a transaction that occurred on Thursday, August 21st. The stock was purchased at an average price of $19.41 per share, with a total value of $98,525.16. Following the acquisition, the chief financial officer owned 213,065 shares in the company, valued at approximately $4,135,591.65. The trade was a 2.44% increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. 32.70% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the business. GAMMA Investing LLC lifted its holdings in shares of OrthoPediatrics by 4,618.2% in the 1st quarter. GAMMA Investing LLC now owns 10,616 shares of the company’s stock valued at $261,000 after acquiring an additional 10,391 shares during the last quarter. Goldman Sachs Group Inc. lifted its holdings in shares of OrthoPediatrics by 112.3% in the 1st quarter. Goldman Sachs Group Inc. now owns 200,439 shares of the company’s stock valued at $4,937,000 after acquiring an additional 106,041 shares during the last quarter. Harbor Capital Advisors Inc. lifted its holdings in shares of OrthoPediatrics by 116.5% in the 2nd quarter. Harbor Capital Advisors Inc. now owns 333,959 shares of the company’s stock valued at $7,173,000 after acquiring an additional 179,733 shares during the last quarter. Invesco Ltd. lifted its holdings in shares of OrthoPediatrics by 12.1% in the 1st quarter. Invesco Ltd. now owns 18,349 shares of the company’s stock valued at $452,000 after acquiring an additional 1,986 shares during the last quarter. Finally, SG Americas Securities LLC lifted its holdings in shares of OrthoPediatrics by 175.0% in the 1st quarter. SG Americas Securities LLC now owns 20,039 shares of the company’s stock valued at $494,000 after acquiring an additional 12,753 shares during the last quarter. Institutional investors own 69.05% of the company’s stock.

OrthoPediatrics Trading Up 4.7%

Shares of KIDS stock opened at $18.77 on Friday. OrthoPediatrics has a 52-week low of $16.59 and a 52-week high of $32.00. The company has a debt-to-equity ratio of 0.27, a quick ratio of 3.43 and a current ratio of 6.66. The firm has a market capitalization of $470.56 million, a PE ratio of -10.49 and a beta of 1.02. The stock has a fifty day simple moving average of $19.87 and a two-hundred day simple moving average of $21.27.

OrthoPediatrics (NASDAQ:KIDS) last issued its quarterly earnings results on Tuesday, August 5th. The company reported ($0.11) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.17) by $0.06. OrthoPediatrics had a negative return on equity of 6.36% and a negative net margin of 18.92%.The business had revenue of $61.08 million during the quarter, compared to analyst estimates of $61.40 million. OrthoPediatrics has set its FY 2025 guidance at EPS. On average, analysts predict that OrthoPediatrics will post -0.93 EPS for the current fiscal year.

About OrthoPediatrics

OrthoPediatrics Corp., a medical device company, engages in designing, developing, and marketing anatomically appropriate implants, instruments, and specialized braces for children with orthopedic conditions in the United States and internationally. The company offers pediatric trauma and deformity correction products; scoliosis procedures for the treatment of spinal deformity; and sports medicine and other products.